Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.59 |
| ▸ | GABRP | O00591 | 5/20 | 0.41 |
| ▸ | GABRD | O14764 | 5/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.41 |
| ▸ | GABRE | P78334 | 5/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522209 | 1.00 | PLAU (0.59) | PLAUGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL29860451 | 0.84 | PLAU (0.47) | PLAUGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL26963253 | 0.84 | PLAU (0.47) | PLAUGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11774613 | 0.83 | PLAU (0.65) | PLAUKDM4EKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL17501714 | 0.83 | AKR1B1 (0.49) | PLAUGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL10256130 | 0.83 | PLAU (0.46) | PLAUGABRPGABRDGABRA1GABRB1 | |
| Dibenzoylmethane SCHEMBL29033398 | 0.82 | CYP3A4 (0.50) | PLAUKDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL11922306 | 0.81 | ATR (0.46) | PLAUGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3632923 | 0.79 | MEN1 (0.43) | PLAUGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30206297 | 0.79 | GRM5 (0.42) | PLAUGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303570-B2 | Compositions and methods for assessing eye vasculature | MEDIBEACON INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20230132384-A9 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC. | 2023-04-27 | — | — | US | disclosed |
| US-20220016269-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC (US) | 2022-01-20 | — | — | US | disclosed |
| US-11160880-B2 | Compositions and methods for assessing eye vasculature | MEDIBEACON INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3245200-B1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-10 | — | — | EP | disclosed |
| US-10898591-B2 | Compositions and methods for assessing eye vasculature | MEDIBEACON INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200155708-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155709-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC. | 2020-05-21 | — | — | US | disclosed |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON INC. (US) | 2020-04-14 | — | — | US | disclosed |
| EP-3245202-B1 | TETRASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2020-03-11 | — | — | EP | disclosed |
| EP-1836175-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT, INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006071759-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-3948895-A | CURING AGENTS FOR EPOXY RESINS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
| US-3948895-A | CURING AGENTS FOR EPOXY RESINS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
| US-3948895-A | CURING AGENTS FOR EPOXY RESINS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160880-B2 | Compositions and methods for assessing eye vasculature | LIPG, FLT4, FABP3 | PLAU 252/4885GABRP 3598/4885GABRD 4467/4885 |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | GLS, CYP4F12, XDH | PLAU 1398/4885GABRP 3744/4885GABRD 4521/4885 |
| US-20230132384-A9 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | LIPG, FLT4, FABP3 | PLAU 252/4885GABRP 3598/4885GABRD 4467/4885 |
| US-10898591-B2 | Compositions and methods for assessing eye vasculature | LIPG, FLT4, FABP3 | PLAU 252/4885GABRP 3598/4885GABRD 4467/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | PLAU 4258/4885GABRP 2375/4885GABRD 3990/4885 |
| US-20200155709-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | LIPG, FLT4, FABP3 | PLAU 252/4885GABRP 3598/4885GABRD 4467/4885 |
| US-20200155708-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | LIPG, FLT4, FABP3 | PLAU 252/4885GABRP 3598/4885GABRD 4467/4885 |
| US-12303570-B2 | Compositions and methods for assessing eye vasculature | LIPG, FLT4, FABP3 | PLAU 252/4885GABRP 3598/4885GABRD 4467/4885 |
| US-20220016269-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | LIPG, FLT4, FABP3 | PLAU 252/4885GABRP 3598/4885GABRD 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.